Power Players all getting in here it looks like. VERY cheap BIO at .13 and .14. Their drug ANX-530 is due for FDA decision by the end of the year. ANX recently gathered cash from an offering so no worries of BK. They are presenting at 2 different investor conferences next week as well. Should run from these prices.